State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
Department of Obstetrics and Gynecology, Southwest Hospital, Army Military Medical University, Chongqing, China.
Int J Hyperthermia. 2024;41(1):2299479. doi: 10.1080/02656736.2023.2299479. Epub 2024 Jan 2.
To quantify the reintervention rate and analyze the risk factors for reintervention after high-intensity focused ultrasound (HIFU) ablation of uterine fibroids.
Eighteen studies were selected from the seven databases. A meta-analysis was applied to synthesize the reintervention rates for fibroids across various follow-up durations. Subgroup-analysis was conducted based on the year of surgery, sample size, guide methods, and non-perfusion volume ratio (NPVR). Signal intensity of T2-weighted imaging (T2WI) was independently evaluated for reintervention risk.
The study enrolled 5216 patients with fibroids treated with HIFU. There were 3247, 1239, 1762, and 2535 women reaching reintervention rates of 1% (95% confidence interval (CI): 1-1), 7% (95% CI: 4-11), 19% (95% CI: 11-27), and 29% (95% CI: 14-44) at 12, 24, 36, and 60-month after HIFU. The reintervention rates of patients treated with US-guided HIFU (USgHIFU) were significantly lower than those of patients treated with MR-guided focused ultrasound surgery (MRgFUS). When the NPVR of fibroids was over 50%, the reintervention rates at 12, 36 and 60-month after HIFU were 1% (95% CI: 0.3-2), 5% (95% CI: 3-8), and 15% (95% CI: 9-20). The reintervention risk for hyper-intensity fibroids on T2WI was 3.45 times higher (95% CI: 2.7-4.39) for hypo-/iso-intensity fibroids.
This meta-analysis showed that the overall reintervention rates after HIFU were acceptable and provided consultative suggestions regarding treatment alternatives for patients with fibroids. Subgroup-analysis revealed that USgHIFU, NPVR ≥ 50%, and hypo-/iso-intensity of fibroids on T2WI were significant factors in reducing reintervention.
PROSPERO, CRD42023456094.
定量高强度聚焦超声(HIFU)消融子宫肌瘤后的再干预率,并分析再干预的风险因素。
从 7 个数据库中选择了 18 项研究。应用荟萃分析综合了不同随访时间内子宫肌瘤的再干预率。基于手术年份、样本量、引导方法和非灌注体积比(NPVR)进行了亚组分析。T2 加权成像(T2WI)的信号强度被独立评估为再干预风险因素。
这项研究共纳入了 5216 名接受 HIFU 治疗的子宫肌瘤患者。12、24、36 和 60 个月后,1%(95%置信区间(CI):1-1)、7%(95% CI:4-11)、19%(95% CI:11-27)和 29%(95% CI:14-44)的再干预率分别见于 3247、1239、1762 和 2535 名女性。US 引导 HIFU(USgHIFU)治疗的患者再干预率明显低于 MR 引导聚焦超声手术(MRgFUS)治疗的患者。当肌瘤的 NPVR 超过 50%时,12、36 和 60 个月后的再干预率分别为 1%(95% CI:0.3-2)、5%(95% CI:3-8)和 15%(95% CI:9-20)。T2WI 上高信号肌瘤的再干预风险是低/等信号肌瘤的 3.45 倍(95% CI:2.7-4.39)。
这项荟萃分析显示,HIFU 后的总体再干预率是可以接受的,并为子宫肌瘤患者的治疗选择提供了咨询建议。亚组分析表明,USgHIFU、NPVR≥50%和 T2WI 上低/等信号肌瘤是降低再干预的显著因素。
PROSPERO,CRD42023456094。